You are here: Industry Insights > Keytruda

News List

Keytruda prolongs recurrence-free survival in melanoma, study shows pharmatimes
April 17, 2018
MSD and the European Organisation for Research and Treatment of Cancer have released new data showing that the anti-PD-1 therapy Keytruda significantly prolonged recurrence-free survival in patients with high-risk stage III melanoma.
Merck May Have Too Many Eggs in Its Keytruda Basket biospace
April 17, 2018
In 2017, Merck & Co.’s wonder drug, Keytruda (pembrolizumab), brought in $3.8 billion, or about 9 percent of the company’s total revenue.
Merck & Co. details positive late-stage data for Keytruda in adjuvant melanoma firstwordpharma
April 16, 2018
Merck & Co. announced Sunday that Keytruda significantly prolonged recurrence-free survival, reducing the risk of disease recurrence or death by 43 percent compared to placebo, in a Phase III study as adjuvant therapy in patients with resected
Merck’s KEYTRUDA monotherapy trial meets primary endpoint expressbpd
April 11, 2018
Merck Announces Key Three Phase KEYNOTE-042 Trial to Assess Merck's Anti-PD-1 Therapy KEYTRUDA as first-line therapy for locally advanced or metastatic non-small cell lung cancer Monotherapy
MSD’s Keytruda bags another trial success in NSCLC pharmatimes
April 11, 2018
MSD’s Keytruda has significantly increased overall survival in patients with lung cancer expressing any level of PD-L1 when used as monotherapy in the first-line setting, potentially significantly increasing the drug’s treatment scope.
SMC nod for Novartis’ Kisqali, MSD’s Keytruda pharmatimes
March 14, 2018
The SMC said it was highlighted during the PACE meeting that Kisqali can increase the period of time patients have until their condition progresses and as an oral treatment is easy to administer.
NICE minded to reject Keytruda for classical Hodgkin lymphoma pharmatimes
March 13, 2018
Cost regulators for NHS therapies in England and Wales say they are minded not to recommend funding for MSD’s Keytruda as a treatment for classical Hodgkin lymphoma, because its cost-effectiveness is uncertain
Merck shows canny cancer strategy in $5.76bn Eisai milestones deal pharmaphorum
March 12, 2018
Merck & Co and Eisai have reached a deal to co-develop and jointly market Keytruda and Lenvima in a deal that could generate $5.76 billion for the Japanese pharma company
MSD’s interim Keytruda combo data spooks Roche and BMS pharmafile
January 17, 2018
When PD-1/L1 treatments first came on the market, there was a race to snaffle as many indications as possible for the therapies
MSD withdraws EU application of Keytruda combination for the treatment of NSCLC pharmafile
October 31, 2017
MSD has been forced to withdraw its EU marketing application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC),

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page